SeqLL, which provides a genetic sequencing platform for researching the makeup of diseases, withdrew its plans for an initial public offering on Friday. It had originally filed in April 2019 to raise $8 million by offering 1.4 million shares at a price range of $5.40 to $6.40.
The Woburn, MA-based company was founded in 2013 and booked $1 million in revenue for the 12 months ended June 30, 2019. It had planned to list on the Nasdaq under the symbol SQL. WallachBeth Capital was set to be the sole bookrunner on the deal.
The article Genetic sequencing platform SeqLL withdraws $8 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
